Bioactive Suture with Added Innate Defense Functionality for the Reduction of Bacterial Infection and Inflammation
(2023) In Advanced healthcare materials 12(31).- Abstract
- Surgical site infections (SSI) are a clinical and economic burden. Suture-associated SSI may develop when bacteria colonize the suture surface and form biofilms that are resistant to antibiotics. Thrombin-derived C-terminal peptide (TCP)-25 is a host defense peptide with a unique dual mode of action that can target both bacteria and the excessive inflammation induced by bacterial products. The peptide demonstrates therapeutic potential in preclinical in vivo wound infection models. In this study, the authors set out to explore whether TCP-25 can provide a new bioactive innate immune feature to hydrophilic polyglactin sutures (Vicryl). Using a combination of biochemical, biophysical, antibacterial, biofilm, and anti-inflammatory assays in... (More)
- Surgical site infections (SSI) are a clinical and economic burden. Suture-associated SSI may develop when bacteria colonize the suture surface and form biofilms that are resistant to antibiotics. Thrombin-derived C-terminal peptide (TCP)-25 is a host defense peptide with a unique dual mode of action that can target both bacteria and the excessive inflammation induced by bacterial products. The peptide demonstrates therapeutic potential in preclinical in vivo wound infection models. In this study, the authors set out to explore whether TCP-25 can provide a new bioactive innate immune feature to hydrophilic polyglactin sutures (Vicryl). Using a combination of biochemical, biophysical, antibacterial, biofilm, and anti-inflammatory assays in vitro, in silico molecular modeling studies, along with experimental infection and inflammation models in mice, a proof-of-concept that TCP-25 can provide Vicryl sutures with a previously undisclosed host defense capacity, that enables targeting of bacteria, biofilms, and the accompanying inflammatory response, is shown. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/16901188-cefb-4e6b-91dd-2065545fd899
- author
- organization
-
- Schmidtchen Lab (research group)
- Division of Microbiology, Immunology and Glycobiology - MIG
- Dermatology and Venereology (Lund)
- Lund University Bioimaging Center
- Glucose Transport and Protein Trafficking (research group)
- BioMS (research group)
- Mass Spectrometry
- Physical Chemistry
- MultiPark: Multidisciplinary research focused on Parkinson´s disease
- Medical Microspectroscopy (research group)
- NanoLund: Centre for Nanoscience
- LINXS - Institute of advanced Neutron and X-ray Science
- LTH Profile Area: Nanoscience and Semiconductor Technology
- LU Profile Area: Proactive Ageing
- LU Profile Area: Light and Materials
- Orthopaedics (Lund)
- Clinical and experimental bone healing (research group)
- Building Bone Killing Bugs (research group)
- publishing date
- 2023-09-09
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Advanced healthcare materials
- volume
- 12
- issue
- 31
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- scopus:85171534958
- pmid:37689972
- ISSN
- 2192-2659
- DOI
- 10.1002/adhm.202300987
- language
- English
- LU publication?
- yes
- id
- 16901188-cefb-4e6b-91dd-2065545fd899
- date added to LUP
- 2023-11-12 22:18:51
- date last changed
- 2024-01-09 15:45:08
@article{16901188-cefb-4e6b-91dd-2065545fd899, abstract = {{Surgical site infections (SSI) are a clinical and economic burden. Suture-associated SSI may develop when bacteria colonize the suture surface and form biofilms that are resistant to antibiotics. Thrombin-derived C-terminal peptide (TCP)-25 is a host defense peptide with a unique dual mode of action that can target both bacteria and the excessive inflammation induced by bacterial products. The peptide demonstrates therapeutic potential in preclinical in vivo wound infection models. In this study, the authors set out to explore whether TCP-25 can provide a new bioactive innate immune feature to hydrophilic polyglactin sutures (Vicryl). Using a combination of biochemical, biophysical, antibacterial, biofilm, and anti-inflammatory assays in vitro, in silico molecular modeling studies, along with experimental infection and inflammation models in mice, a proof-of-concept that TCP-25 can provide Vicryl sutures with a previously undisclosed host defense capacity, that enables targeting of bacteria, biofilms, and the accompanying inflammatory response, is shown.}}, author = {{Puthia, Manoj and Petrlova, Jitka and Petruk, Ganna and Butrym, Marta and Samsudin, Firdaus and Andersson, Madeleine Å and Strömdahl, Ann-Charlotte and Wasserstrom, Sebastian and Hartman, Erik and Kjellström, Sven and Caselli, Lucrezia and Klementieva, Oxana and Bond, Peter J. and Malmsten, Martin and Raina, Deepak and Schmidtchen, Artur}}, issn = {{2192-2659}}, language = {{eng}}, month = {{09}}, number = {{31}}, publisher = {{John Wiley & Sons Inc.}}, series = {{Advanced healthcare materials}}, title = {{Bioactive Suture with Added Innate Defense Functionality for the Reduction of Bacterial Infection and Inflammation}}, url = {{http://dx.doi.org/10.1002/adhm.202300987}}, doi = {{10.1002/adhm.202300987}}, volume = {{12}}, year = {{2023}}, }